CVE:ADK DIAGNOS (ADK) Stock Price, News & Analysis → The Secret Energy Firm Wall Street is Keeping Under The Radar (From StocksToTrade) (Ad) Free ADK Stock Alerts C$0.32 +0.01 (+3.23%) (As of 05/27/2024 04:55 PM ET) Add Compare Share Share Today's RangeC$0.31▼C$0.3250-Day RangeC$0.24▼C$0.3552-Week RangeC$0.23▼C$0.59Volume30,000 shsAverage Volume83,851 shsMarket CapitalizationC$24.89 millionP/E RatioN/ADividend Yield0.29%Price TargetC$1.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesStock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider Trades Get DIAGNOS alerts: Email Address Ad StocksToTradeThe Secret Energy Firm Wall Street is Keeping Under The RadarThis firm is now poised to become the industry leader behind one of the biggest energy breakthroughs of the decade… A breakthrough that could soon power humanity for the next 4 billion years.Discover the #1 company leading this revolution About DIAGNOS Stock (CVE:ADK)DIAGNOS Inc. provides software-based services primarily in Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. The company offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy; and allows eye care specialist to visualize both normal retinal landmarks and pathological changes. It also provides various consulting services in the fields of data analysis and artificial intelligence. DIAGNOS Inc. was founded in 1998 and is headquartered in Brossard, Canada.Read More ADK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADK Stock News HeadlinesFebruary 23, 2024 | ca.finance.yahoo.comGot $1,000? 2 Stocks to Buy Now While They’re on SaleFebruary 21, 2024 | finance.yahoo.comDIAGNOS recognized as a Top TSX Venture Exchange CompanyFebruary 9, 2024 | theglobeandmail.comClosing Bell: Diagnos Inc flat on Thursday (ADK)January 16, 2024 | msn.comDiagnos appoints Yves-Stéphane Couture as chief operating officerJanuary 16, 2024 | finance.yahoo.comDIAGNOS Appoints New Chief Operating OfficerDecember 8, 2023 | finance.yahoo.comCanadian Investment Regulatory Organization Trading Halt - ADKNovember 18, 2023 | finance.yahoo.comDIAGNOS Inc. (ADK.V)November 14, 2023 | msn.comThe last government shutdown deadline ousted the House speaker. This week's showdown could be easierNovember 4, 2023 | theglobeandmail.comClosing Bell: Diagnos Inc flat on Friday (ADK)October 24, 2023 | investing.comDiagnos Laboratorium Utama PT Tbk (DGNS)October 7, 2023 | stockhouse.comDIAGNOS AI Retina Analysis is being deployed across Canada's Largest Specialist Care Provider in Diabetes & EndocrinologyOctober 5, 2023 | finance.yahoo.comDIAGNOS AI Retina Analysis is being deployed across Canada’s Largest Specialist Care Provider in Diabetes & EndocrinologySeptember 8, 2023 | baystreet.caDiagnos, Appulse, Bedford at 52-Week HighsJuly 15, 2023 | theglobeandmail.comClosing Bell: Diagnos Inc down on Friday (ADK)July 6, 2023 | markets.businessinsider.comEchelon Wealth Partners Believes Diagnos (ADK) Won’t Stop HereMay 17, 2023 | finance.yahoo.comDIAGNOS and IRIS, The Visual Group strengthen partnership with the launch of “IRIS-ai powered by DIAGNOS”May 15, 2023 | baystreet.caTMX, Arrow, CPKC at 52-Week Highs on NewsMay 11, 2023 | usatoday.comMichael J. Fox: Do you have Parkinson's? New test is 'breakthrough' in diagnosing disease.May 4, 2023 | theglobeandmail.comClosing Bell: Diagnos Inc up on Wednesday (ADK)May 2, 2023 | theglobeandmail.comClosing Bell: Diagnos Inc up on Monday (ADK)April 28, 2023 | theglobeandmail.comClosing Bell: Diagnos Inc up on Thursday (ADK)April 19, 2023 | theglobeandmail.comClosing Bell: Diagnos Inc up on Tuesday (ADK)February 28, 2023 | finance.yahoo.comDIAGNOS and ÉTS Unveil a Method to Adapt Deep Learning Algorithms According to the Diversity of ContextsDecember 15, 2022 | finance.yahoo.comDIAGNOS Provides Additional Information to the Closing of Private PlacementNovember 6, 2022 | reuters.comADK.V - Diagnos Inc | Stock Price & Latest News | ReutersSee More Headlines Receive ADK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DIAGNOS and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today5/28/2024Next Earnings (Estimated)7/11/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Health Information Services Sub-IndustryN/A Current SymbolCVE:ADK CUSIPN/A CIKN/A Webwww.diagnos.ca Phone+1-450-6788882FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price TargetC$1.50 High Stock Price TargetC$1.50 Low Stock Price TargetC$1.50 Potential Upside/Downside+368.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)C($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-3,040,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-150.84% Debt Debt-to-Equity Ratio245.28 Current Ratio0.70 Quick Ratio0.68 Sales & Book Value Annual SalesC$577,486.00 Price / Sales43.09 Cash FlowC$0.01 per share Price / Cash Flow60.00 Book ValueC($0.04) per share Price / Book-8.00Miscellaneous Outstanding Shares77,770,000Free FloatN/AMarket CapC$24.89 million OptionableNot Optionable Beta-0.43 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Andre LarenteCEO, President & Executive ChairmanMr. Marc-André MassueVP of Finance, CFO & SecretaryMr. Yves-Stéphane CoutureChief Operating OfficerMr. Martin BelandDirector of MarketingKey CompetitorsCloudMD Software & ServicesCVE:DOCReliq Health TechnologiesCVE:RHTGeneNewsTSE:GENCovalon TechnologiesCVE:COVAptose BiosciencesTSE:APSView All CompetitorsInsidersTristram CoffinSold 800,000 sharesTotal: C$240,000.00 ($0.30/share)View All Insider Transactions ADK Stock Analysis - Frequently Asked Questions Should I buy or sell DIAGNOS stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DIAGNOS in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ADK shares. View ADK analyst ratings or view top-rated stocks. What is DIAGNOS's stock price target for 2024? 1 brokers have issued 1 year price targets for DIAGNOS's stock. Their ADK share price targets range from C$1.50 to C$1.50. On average, they expect the company's share price to reach C$1.50 in the next year. This suggests a possible upside of 368.8% from the stock's current price. View analysts price targets for ADK or view top-rated stocks among Wall Street analysts. How have ADK shares performed in 2024? DIAGNOS's stock was trading at C$0.41 on January 1st, 2024. Since then, ADK stock has decreased by 21.0% and is now trading at C$0.32. View the best growth stocks for 2024 here. When is DIAGNOS's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, July 11th 2024. View our ADK earnings forecast. How were DIAGNOS's earnings last quarter? DIAGNOS Inc. (CVE:ADK) announced its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.01) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.01). The company earned $0.05 million during the quarter, compared to the consensus estimate of $0.10 million. What other stocks do shareholders of DIAGNOS own? Based on aggregate information from My MarketBeat watchlists, some companies that other DIAGNOS investors own include Marijuana Company of America (MCOA), Maxar Technologies (MAXR) and Main Street Capital (MAIN). How do I buy shares of DIAGNOS? Shares of ADK stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (CVE:ADK) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersDigitizing the $11T commodities sector with one tiny stockResource Stock DigestTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy SykesClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceThe Secret Energy Firm Wall Street is Keeping Under The RadarStocksToTradeWARNING about the death of the U.S. dollar…Colonial MetalsNew Options need New Trading StrategiesNetpicksThe 7th Trillion Dollar Company?The Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DIAGNOS Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.